Detalles de la búsqueda
1.
A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.
Pain Med;
17(6): 1112-30, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26814256
2.
Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
Pain Pract;
16(3): 334-44, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25639548
3.
Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
Pain Med;
16(11): 2142-51, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26108255
4.
Response to Crudele et al. Commentary on Gudin et al. "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties".
Pain Med;
18(5): 992-994, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28074029
5.
Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations.
Pain;
163(6): 1006-1018, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34510135
6.
Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations.
Pain Rep;
6(1): e895, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33981929
7.
Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations.
Pain;
161(11): 2446-2461, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32520773
8.
Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.
J Pain;
21(9-10): 931-942, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31843583
9.
Opioid Pharmacology: Developmental Effects on Opioid Metabolism.
Clin J Pain;
35(6): 481-486, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30985400
10.
Number Of Clinical Trial Study Sites Impacts Observed Treatment Effect Size: An Analysis Of Randomized Controlled Trials Of Opioids For Chronic Pain.
J Pain Res;
12: 3161-3165, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31819600
11.
Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
J Opioid Manag;
14(5): 359-372, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30387859
12.
Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone.
J Pain Res;
11: 2051-2059, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30288095
13.
Clinical trial designs and models for analgesic medications for acute pain in neonates, infants, toddlers, children, and adolescents: ACTTION recommendations.
Pain;
159(2): 193-205, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29140927
14.
Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
Drugs Aging;
34(8): 603-613, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28600725
15.
The comparative pharmacokinetics of physical manipulation by crushing of Xtampza® ER compared with OxyContin®.
Pain Manag;
7(6): 461-472, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29171358
16.
Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).
J Clin Pharmacol;
57(4): 500-512, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27669664
17.
Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.
J Pain;
18(11): 1287-1294, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28479207
18.
The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.
J Pain;
18(7): 757-777, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28254585
19.
Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
Curr Med Res Opin;
32(7): 1311-7, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27025986
20.
An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.
Curr Med Res Opin;
32(12): 1975-1982, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27668546